Abnormal Mammogram, Unspecified, Breast Cancer
Conditions
Keywords
screening mammography, biomarker of breast disease
Brief summary
To validate a breath test that predicts risk of breast cancer and an abnormal mammogram.
Detailed description
We will determine the accuracy of volatile organic compounds (VOCs) in the breath as predictors of risk of breast cancer and an abnormal mammogram. Breath samples will be collected using an ultra-clean collection bag and analyzed with gas chromatography surface acoustic wave detection (GC SAW) The study will be performed in two phases: Phase 1: Model-building phase (cross-sectional study): Breath VOCs will be employed to construct multivariate algorithms that distinguish between normal women and those with breast cancer and abnormal screening mammograms. Phase 2: Model-testing phase (cross-sectional study): The predictive accuracy of these algorithms will be tested to predict outcomes in normal women and those with breast cancer and abnormal screening mammograms.
Interventions
DEVICEBreathX test for breath VOCs
Breath samples are collected into an ultra-clean bag and breath VOCs are analyzed with GC-SAW.
Sponsors
Mount Vernon Cancer Centre
Zuyderland Medical Centre
University of Erlangen-Nürnberg
Menssana Research, Inc.
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Inclusion criteria
Group 1: Normal screening mammogram Inclusion Criteria: 1. Female aged 18 years or older 2. Understands the study, and is willing to give written informed consent to participate 3. If a screening mammogram was performed during the preceding six month period, then the results were reported as normal (BIRADS 1 or 2) 4. If a screening mammogram was not performed during the preceding six month period, then approves collection of the results of a screening mammogram if and when it is performed subsequently\*. 5. Approves collection of relevant additional data for clinical research record if and when these data become available, including results of imaging studies, breast biopsy, and other relevant biomarker data e.g. status of BRCA1, BRCA2, HER2 and receptors (ER+ or ER-) and progesterone (PgR+ or PgR-) \* If a subsequent screening mammogram is reported as abnormal, the subject will be transferred to Group 2 for analysis of data.
Exclusion criteria
1. Previous history of an abnormal mammogram, breast disease, or breast biopsy 2. Previous history of cancer of any site, with the exception of basal cell carcinoma of skin 3. Concurrent serious or potentially life-threatening disease (e.g. severe cardiac or infectious disease) 4. Concurrent acute pulmonary disease (e.g. influenza, influenza-like illness, acute asthma, or pneumonitis). 5. General anesthesia during the 10-day period prior to breath collection. Group 2: Abnormal screening mammogram Inclusion Criteria: Female aged 18 years or older 1. Understands the study, and is willing to give written informed consent to participate 2. Abnormal screening mammogram during preceding six months (BIRADS 3-6) 3. Approves collection of relevant additional data for clinical research record if and when it becomes available, including results of imaging studies, biopsy results, and other relevant biomarker data e.g. status of BRCA1, BRCA2, HER2 and receptors (ER+ or ER-) and progesterone (PgR+ or PgR-)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BREATH TEST TO PREDICT BREAST CANCER | 2 years | Determination of the sensitivity, specificity, and positive and negative predictive values of a breath test for biomarkers that predict the risk of an abnormal mammogram. |
| BREATH TEST TO PREDICT OUTCOME OF MAMMOGRAPHY | 2 years | Determination of the sensitivity, specificity, and positive and negative predictive values of a breath test for biomarkers that predict the risk of an biopsy-proven breast cancer |
Countries
Germany, Netherlands, United Kingdom
Contacts
Primary ContactMichael Phillips, MD
Backup ContactJonah Phillips, MBA
Outcome results
None listed